Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 411-420 of 2766 for cancer

Edit search filters
  1. A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

    Scottsdale/Phoenix, AZ

  2. A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)

    Jacksonville, FL, Rochester, MN

  3. Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery

    Eau Claire, WI

  4. Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

    La Crosse, WI

  5. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study

    Jacksonville, FL

  6. Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

    Rochester, MN

  7. Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).

    Scottsdale/Phoenix, AZ

  8. Study of Adjuvant Regorafenib vs Placebo in Patients with Node Positive Esophageal Cancer who Completed Pre-operative Therapy

    Rochester, MN

  9. Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies

    Scottsdale/Phoenix, AZ

  10. A Study to Determine Immune System Response in Newly Diagnosed Lymphoma Patients Starting First Line Therapy

    Rochester, MN

.

Mayo Clinic Footer